FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Beginner's Guide to Peptide Therapy [2026] Major peptide regulatory news this week. The FDA announced on April 15 that it will remove 12 peptides from Category 2 of the 503A bulk drug substances list after seven calendar days. Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn BREAKING: The FDA just reversed their 2023 peptide ban. 12 peptides pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu 5. MOTS C 6.